Benign prostatic hyperplasia (BPH) is a common urological disease in middle-aged and elderly men. Its incidence increases continuously with age, which significantly affects patients' quality of life and may even be life-threatening. As population aging intensifies, BPH has become an increasingly prominent public health problem. Existing studies suggest that the occurrence and progression of BPH are associated with multiple factors. However, there is currently a lack of systematic and standardized guidance on managing risk factors for BPH in clinical practice.  Focusing on existing evidence and integrating clinical experts' opinions, this consensus formulates 20 items recommendations aiming to promote the standardized management of risk factors influencing the occurrence and progression of BPH, in order to delay its age of onset, slow clinical progression, and reduce the disease burden.

1. Zi H, Liu MY, Luo LS, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021[J]. Mil Med Res, 2024, 11(1): 64.

2. 中国研究型医院学会泌尿外科学专业委员会,中国医疗保健国际交流促进会泌尿健康促进分会,中国医疗保健国际交流促进会循证医学分会,等. 中国良性前列腺增生症经尿道等离子双极电切术治疗指南(2018标准版)[J]. 中华医学杂志, 2018, 98(20): 1549-1560. [The Professional Committee of Urology Chinese Research Hospital Association, Urology Health Promotion Branch China International Exchange and Promotive Association for Medical and Health Care, Evidence-Based Medicine Branch, China International Exchange and Promotion Association for Medical and Healthcare, et al. Transurethral bipolar plasmakinetic prostatectomy treatment for benign prostatic hyperplasia in Chinese: development of a national evidence-based clinical practice guideline (2018 Standard Version)[J]. National Medical Journal of China, 2018, 98(20): 1549-1560]

3. Zeng XT, Jin YH, Liu TZ, et al. Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)[J]. Mil Med Res, 2022, 9(1): 14.

4. Huang JF, Shen N, Zhao JM, et al. Relationship between severity of obstructive sleep apnea and benign prostatic hyperplasia[J]. Sleep Breath, 2023, 27(1): 363-369.

5. 何立浩,罗权平,李忠诚,等. 上海吴泾地区50岁及以上男性良性前列腺增生流行病学调查和影响因素分析[J]. 上海医药, 2023, 44(14): 46-49. [He LH, Luo QP, Li ZC, et al. Epidemiological investigation of benign prostatic hyperplasia in men aged 50 and over and analysis of influencing factors in Wujing Area, Shanghai[J]. Shanghai Medical & Pharmaceutical Journal, 2023, 44(14): 46-49.]

6. 周清,马爱霞. 中国中老年人群良性前列腺增生危险因素分析 [J]. 上海医药, 2014, (13): 56-57, 69. [Zhou Q, Ma AX. Analysis of risk factors for benign prostatic hyperplasia in Chinese elderly people[J]. Shanghai Medical & Pharmaceutical Journal, 2014, (13): 56-57, 69.]

7. 刘妍,田心,徐勇,等. 天津市农村地区良性前列腺增生症危险因素分析[J]. 山东医药, 2010, 50(22): 4-5. [Liu Y, Tian X, Xu  Y, et  al. Risk factors analysis of benign prostatic hyperplasia in the suburb of Tianjin[J]. Shandong Medical Journal, 2010, 50(22): 4-5.]

8. 方毅. 老年良性前列腺增生症与心血管危险因素相关性临床研究[D]. 乌鲁木齐: 新疆医科大学, 2010. [Fang Y. Benign prostatic hyperplasia and cardiovascular risk factors[D]. Urumqi: Xinjiang Medical University, 2010.]

9. 徐勇,张志宏,程茹,等. 天津市农村地区良性前列腺增生患病情况及相关因素调查[J]. 中华泌尿外科杂志, 2009, 30(11): 761-764. [Xu Y, Zhang ZH, Cheng R, et al. Prevalence of benign prostate hyperplasia and its relative factors in rural areas of Tianjin in 2008[J]. Chinese Journal of Urology, 2009, 30(11): 761-764.]

10. Hong J, Kwon S, Yoon H, et al. Risk factors for benign prostatic hyperplasia in South Korean men[J]. Urol Int, 2006, 76(1): 11-19.

11. 于普林,郑宏,苏鸿学,等. 中国六城市老年人前列腺增生的患病率及相关因素[J]. 中华流行病学杂志, 2000, 21(4): 276-279. [Yu  PL, Zheng H, Su HX, et al. Prevalence of prostatic hyperplasia and its relative factors in six cities of China in 1997[J]. Chinese Journal of Epidemiology, 2000, 21(4): 276-279.]

12. Huang Q, Li BH, Wang YB, et al. Clinical biomarker-based biological aging and risk of benign prostatic hyperplasia: a large prospective cohort study[J]. Aging Med (Milton), 2024, 7(3): 393-405.

13. Platz EA, Kawachi I, Rimm EB, et al. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study[J]. J Urol, 2000, 163(2): 490-495.

14. 钟甘平,陈雪红,王家吉,等. 兰州地区前列腺增生和前列腺癌发病情况及发病因素分析[J]. 标记免疫分析与临床, 2003, 10(2): 82-85. [Zhong GP, Chen XH, Wang JJ, et al. Prevalence of benign prostatic hyperplasia and prostate cancer and its relative factors in Lanzhou[J]. Labeled Immunoassays and Clinical Medicine, 2003, 10(2): 82-85.]

15. 张书贤,喻彬,郭松林,等. 皖南地区不同老年人群良性前列腺增生发病的差异及相关因素[J]. 中华男科学, 2003, 9(1): 45-47. [Zhang SX, Yu B, Guo SL, et al. Comparison of incidence of BPH and related factors between urban and rural inhabitants in district of Wannan[J]. National Journal of Andrology, 2003, 9(1): 45-47.]

16. Yoo S, Oh S, Park J, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men[J]. BJU Int, 2019, 123(1): 140-148.

17. 宁夏,时景璞,吴作艳,等. 沈阳农村60岁以上人群良性前列腺增生危险因素的病例对照研究[J]. 中华流行病学杂志, 2003, 24(4): 276-280. [Ning X, Shi JP, Wu ZY, et al. A case-control study on the risk factors of benign prostatic hyperplasia in the suburb of Shenyang[J]. Chinese Journal of Epidemiology, 2003, 24(4): 276-280.]

18. ElJalby M, Thomas D, Elterman D, et al. The effect of diet on BPH, LUTS and ED[J]. World J Urol, 2019, 37(6): 1001-1005.

19. Das K, Buchholz N. Benign prostate hyperplasia and nutrition[J]. Clin Nutr ESPEN, 2019, 33: 5-11.

20. Bradley CS, Erickson BA, Messersmith EE, et al. Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: a systematic review[J]. J Urol, 2017, 198(5): 1010-1020.

21. 葛梦颍,张程达,侯全亮,等. 良性前列腺增生主要影响因素的Meta分析[J]. 现代预防医学, 2017, 44(10): 1902-1907. [Ge  MY, Zhang CD, Hou QL, et al. Meta-analysis for primary influencing factors of benign prostatic hyperplasia[J]. Modern Preventive Medicine, 2017, 44(10): 1902-1907.]

22. Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia[J]. J Urol, 2009, 182(4): 1463-1468.

23. 李孟谣. 基于孟德尔随机化的饮酒与多种疾病关联的评估及Meta分析[D]. 沈阳: 中国医科大学, 2024. [Li MY. Assessment and Meta-analysis of the association between alcohol consumption and multiple diseases based on Mendelian randomization[D]. Shenyang: China Medical University, 2024.]

24. Xu H, Fu S, Chen Y, et al. Smoking habits and benign prostatic hyperplasia: a systematic review and Meta-analysis of observational studies[J]. Medicine (Baltimore), 2016, 95(32): e4565.

25. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms[J]. Eur Urol, 2008, 53(6): 1228-1235.

26. Tiruneh T, Getachew T, Getahun F, et al. Magnitude and factors associated with benign prostatic hyperplasia among adult male patients visiting Wolaita Sodo University comprehensive specialized hospital southern Ethiopia[J]. Sci Rep, 2024, 14(1): 31556.

27. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men[J]. J Clin Epidemiol, 2001, 54(9): 935-944.

28. 王国民,徐伟刚. 上海市区良性前列腺增生症危险因素调查 [J]. 上海预防医学杂志, 1997, (3): 107-110. [Wang GM, Xu WG. Survey of risk factors for benign prostatic hyperplasia in urban area of Shanghai[J]. Shanghai Journal of Preventive Medicine, 1997, (3): 107-110.]

29. Liao G, Lee PMY, Zhao S, et al. Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia: a case-control study in Hong Kong Chinese males[J]. Prostate, 2021, 81(15): 1214-1224.

30. Zhao D, Han J, Lyu C, et al. Poor sleep patterns are associated with the prevalence of benign prostatic hyperplasia in US aged 40 and older: a cross-sectional study based on NHANES[J]. PLoS One, 2025, 20(2): e0319434.

31. Lin TY, Chen IH, Weng HY, et al. Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study[J]. World J Uro, 2024, 42(1): 126.

32. Lee JH, Won Park Y, Woo Lee S, et al. Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: a propensity score-matched analysis[J]. Prostate Int, 2022, 10(2): 92-95.

33. Fu E, Cheng CM, Chung CH, et al. Association of chronic periodontitis with prostatic hyperplasia and prostatitis: a population-based cohort study in Taiwan[J]. J Periodontol, 2021, 92(1): 72-86.

34. Rule AD, Jacobson DJ, Roberts RO, et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men[J]. Kidney Int, 2005, 67(6): 2376-2382.

35. Li J, Peng L, Cao D, et al. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and Meta-analysis[J]. Aging Male, 2020, 23(5): 1388-1399.

36. 林东,曹亮,呼廷辉,等. 代谢综合征及其组分与良性前列腺增生相关下尿路症状之间的关系: Meta分析[J]. 中国全科医学, 2020, 23(S2): 68-74. [Lin D, Cao L, Hu YH, et al. Relationship between metabolic syndrome and its components and lower urinary tract symptoms associated with benign prostatic enlargement: a Meta-analysis[J]. Chinese General Practice, 2020, 23(S2): 68-74.]

37. Wu S, He H, Wang Y, et al. Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a Meta-analysis[J]. J Int Med Res, 2019, 47(11): 5389-5399.

38. 龙其成. 前列腺增生与代谢综合征相关性研究及其电切术中膀胱造瘘的获益探讨[D]. 广州: 南方医科大学, 2016. [Long QC. Studies of relationship between benign prostatic hyperplasia andmetabolic syndrome and benefit of cystostomy to its electroscission[D]. Guangzhou: Southern Medical University, 2016.]

39. 柯孟婷,孙家忠,李杨. 代谢综合征与前列腺增生相关性的Meta分析[J]. 现代泌尿外科杂志, 2016, 21(1): 42-46. [Ke MT, Sun JZ, Li Y. A Meta-analysis on the correlation between metabolic syndrome and benign prostatic hyperplasia[J]. Journal of Modern Urology, 2016, 21(1): 42-46.]

40. Zou C, Gong D, Fang N, et al. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients[J]. World J Urol, 2016, 34(2): 281-289.

41. Wang JY, Fu YY, Kang DY. The association between metabolic syndrome and characteristics of benign prostatic hyperplasia: a systematic review and Meta-analysis[J]. Medicine (Baltimore), 2016, 95(19): e3243.

42. Russo GI, Castelli T, Urzì D, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and Meta-analysis[J]. Aging Male, 2015, 18(4): 207-216.

43. He J, Pan X, Liu D, et al. Association between metabolic syndrome and risk of benign prostatic hyperplasia: a prospective cohort study of 163 975 participants[J]. J Glob Health, 2025, 15: 04275.

44. Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and Meta-analysis[J]. BJU Int, 2015, 115(1): 24-31.

45. Wang S, Mao Q, Lin Y, et al. Body mass index and risk of BPH: a Meta-analysis[J]. Prostate Cancer Prostatic Dis, 2012, 15(3): 265-272.

46. 伍锡鹏,邹闻达,黄文琳,等. 体质量指数对良性前列腺增生体积影响的Meta分析[J]. 国际泌尿系统杂志, 2025, 45(3): 37-41. [Wu XP, Zou WD, Huang WL, et al. Meta-analysis of the effect of body mass index on the prostate volume of benign prostatic hyperplasia[J]. International Journal of Urology and Nephrology, 2025, 45(3): 37-41. ]

47. Wang H, Tang R, Hou H, et al. Central obesity and its association with benign prostatic hyperplasia: insights from a cross-sectional study of NHANES 2001-2008[J]. Aging Male, 2025, 28(1): 2498943.

48. 李娟,陈平,张卫兵. 糖尿病与前列腺增生的相关性分析[J]. 武汉大学学报(医学版), 2021, 42(2): 338-344. [Li J, Chen P, Zhang  WB. Association between diabetes mellitus and benign prostatic hyperplasia: a Meta-analysis[J]. Medical Journal of Wuhan University, 2021, 42(2): 338-344.]

49. Xin C, Fan H, Xie J, et al. Impact of diabetes mellitus on lower urinary tract symptoms in benign prostatic hyperplasia patients: a Meta-analysis[J]. Front Endocrinol (Lausanne), 2022, 12: 741748.

50. 李华福,谢群,叶啸,等. 糖尿病对良性前列腺增生患者下尿路症状影响的Meta分析[J]. 中华肥胖与代谢病电子杂志, 2017, 3(2): 97-104. [Li HF, Xie Q, Ye X, et al. Meta analysis of the influence of diabetes mellitus on lower urinary tract symptoms of patients with benign prostatic hyperplasia[J]. Chinese Journal of Obesity and Metabolic Diseases, 2017, 3(2): 97-104.]

51. Erbay G, Ceyhun G. Association between hyperlipidemia and prostatic enlargement: a case-control study[J]. Urologia, 2022, 89(1): 58-63.

52. Shih HJ, Huang CJ, Lin JA, et al. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia[J]. Prostate, 2018, 78(2): 113-120.

53. 拓西平. 部队离休干部高脂血症与良性前列腺增生的现况调查与相关性分析[D]. 上海: 第二军医大学, 2012. [Tuo XP. The status quo and correlation analysis of hyperlipidemia and benign prostatic hyperplasia in retired military officers[D]. Shanghai: Naval Medical University, 2012.]

54. 齐建军. 胰岛素抵抗综合征与良性前列腺增生的相关性[D].锦州:辽宁医学院, 2011. [Qi JJ. Interrelationships between insulin resistant syndrome and benign prostatic hyperplasia[D]. Jinzhou: Liaoning Medical University, 2011.]

55. Besiroglu H, Kadihasanoglu M. Is there a link between non-alcoholic fatty liver disease and benign prostate hyperplasia/lower urinary tract symptoms: a systematic review and a Meta-analysis[J]. Metab Syndr Relat Disord, 2023, 21(7): 370-377.

56. Byun SH, Min C, Bang W, et al. A cross-sectional study for association between periodontitis and benign prostatic hyperplasia using the Korean genome and epidemiology study data[J]. Coatings, 2022, 12(2): 265.

57. 邬兰. 牙周病与良性前列腺增生的相关性研究[D]. 武汉: 武汉大学, 2020. [Wu L. Study on the correlation between periodontal disease and benign prostatichyperplasia[D]. Wuhan: Wuhan University,2020.]

58. Kwon MJ, Kang HS, Choi HG, et al. Chronic periodontitis as a risk factor for benign prostatic hyperplasia: a cohort study[J]. J Clin Med, 2025, 14(4): 1279.

59. Wang SY, Cai Y, Hu X, et al. P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6/IL-6R pathway[J]. Mil Med Res, 2024, 11(1): 30.

60. Wei H, Tian G, Xu S, et al. Evaluation of bi-directional causal association between periodontitis and benign prostatic hyperplasia: epidemiological studies and two-sample Mendelian randomization analysis[J]. Front Genet, 2024, 15: 1326434.

61. Chou PS, Chang WC, Chou WP, et al. Increased risk of benign prostate hyperplasia in sleep apnea patients: a nationwide population-based study[J]. PLoS One, 2014, 9(3): e93081.

62. Peng YH, Huang CW, Liao WC, et al. Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study[J]. BMJ Open, 2017, 7(6): e015581.

63. Jin T, Wu T, Luo Z, et al. Association between male pattern baldness and prostate disease: a Meta-analysis[J]. Urol Oncol, 2018, 36(2): 80. e7-80. e15.

64. Bellos TC, Tzelves LI, Manolitsis IS, et al. Frailty and benign prostatic hyperplasia: the thrilling underlying impact[J]. Arch Ital Urol Androl, 2022, 94(3): 345-349.

65. Yang X, Zhang Q, Jiang G, et al. The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: a Meta-analysis[J]. Medicine (Baltimore), 2019, 98(18): e15502.

66. Nørgaard M, Darvalics B, Thomsen RW. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study[J]. BMJ Open, 2020, 10(12) :e041875.

67. Nygård LH, Talala K, Taari K, et al. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia[J]. Prostate, 2017, 77(9): 1029-1035.